Biomaterial Database

Current knowledge on Hashimoto's encephalopathy: a literature review. 2018

Isabel Pinedo-Torres, and José Luis Paz-Ibarra

Departamento de Endocrinología, Hospital Nacional Daniel Alcides Carrión, Callao, Perú. Address: Avenida del pacífico 180, Torre 14, Departamento 704, Condominios Parques de la Huaca, San Miguel, Lima, Perú. Email: isabel_pt_5@hotmail.com.

Hashimoto's encephalopathy is a rare disease, with a reported prevalence of 2.1 per 100 000. Clinical manifestations include confusion, decreased state of consciousness, cognitive deficit, seizures, myoclonus, ataxia, and focal neurological deficits. Due to the wide variety of signs and symptoms, clinical diagnostic suspicion is essential. Diagnosis is based on three pillars: the presence of neurological clinical manifestations after ruling out other causes of encephalopathy. 2) Presence of increased antithyroid antibodies. 3) Significant clinical improvement after the administration of immunomodulation. The treatment of Hashimoto's encephalopathy pursues two objectives: to control the autoimmune process and to control the complications of the disease. Although in most cases recovery is complete with treatment, the risk of relapse can range from 12.5 to 40% in follow-ups to 2 years.

UI	MeSH Term	Description	Entries
D007155	Immunologic Factors	Biologically active substances whose activities affect or play a role in the functioning of the immune system.	Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D012008	Recurrence	The return of a sign, symptom, or disease after a remission.	Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D004660	Encephalitis	Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	Inflammation, Brain,Rasmussen Syndrome,Brain Inflammation,Encephalitis, Rasmussen,Rasmussen Encephalitis,Rasmussen's Syndrome,Brain Inflammations
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323	Autoantibodies	Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.	Autoantibody
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D050031	Hashimoto Disease	Chronic autoimmune thyroiditis, characterized by the presence of high serum thyroid AUTOANTIBODIES; GOITER; and HYPOTHYROIDISM.	Hashimoto's Disease,Chronic Lymphocytic Thyroiditis,Hashimoto Struma,Hashimoto Thyroiditis,Hashimoto's Struma,Hashimoto's Syndrome,Chronic Lymphocytic Thyroiditides,Disease, Hashimoto,Disease, Hashimoto's,Hashimoto Syndrome,Hashimoto Thyroiditides,Hashimoto's Syndromes,Hashimotos Disease,Hashimotos Syndrome,Lymphocytic Thyroiditides, Chronic,Lymphocytic Thyroiditis, Chronic,Syndrome, Hashimoto's,Syndromes, Hashimoto's,Thyroiditides, Chronic Lymphocytic,Thyroiditides, Hashimoto,Thyroiditis, Chronic Lymphocytic,Thyroiditis, Hashimoto